The Goldman Sachs Group Issues Positive Forecast for Arcus Biosciences (NYSE:RCUS) Stock Price

Arcus Biosciences (NYSE:RCUS) had its price target increased by The Goldman Sachs Group from $30.00 to $34.00 in a report issued on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

RCUS has been the topic of several other research reports. Wedbush raised their price objective on shares of Arcus Biosciences from $37.00 to $41.00 and gave the company an “outperform” rating in a research report on Thursday, April 2nd. HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of Arcus Biosciences in a research report on Monday, March 2nd. Leerink Partners set a $47.00 price objective on shares of Arcus Biosciences in a research report on Monday, April 20th. Morgan Stanley restated an “equal weight” rating and set a $20.00 price objective (down from $23.00) on shares of Arcus Biosciences in a research report on Thursday, January 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.11.

Arcus Biosciences Stock Performance

Shares of RCUS stock traded up $0.57 during trading on Thursday, reaching $25.35. 424,655 shares of the company’s stock traded hands, compared to its average volume of 1,250,184. The company has a market capitalization of $3.19 billion, a P/E ratio of -7.97 and a beta of 0.87. The company has a current ratio of 4.04, a quick ratio of 4.36 and a debt-to-equity ratio of 0.19. The firm’s 50-day moving average is $22.93 and its 200 day moving average is $22.10. Arcus Biosciences has a 1 year low of $7.91 and a 1 year high of $28.72.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative net margin of 156.36% and a negative return on equity of 68.97%. The business had revenue of $17.00 million for the quarter, compared to analysts’ expectations of $29.49 million. During the same quarter in the previous year, the company posted ($1.14) earnings per share. The business’s quarterly revenue was down 39.3% compared to the same quarter last year. Equities research analysts expect that Arcus Biosciences will post -3.52 EPS for the current year.

Hedge Funds Weigh In On Arcus Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of RCUS. Hantz Financial Services Inc. increased its position in shares of Arcus Biosciences by 121.9% during the fourth quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after buying an additional 881 shares during the period. SBI Securities Co. Ltd. increased its position in shares of Arcus Biosciences by 13,547.6% during the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after buying an additional 2,845 shares during the period. T. Rowe Price Investment Management Inc. purchased a new position in shares of Arcus Biosciences during the fourth quarter valued at about $39,000. KBC Group NV purchased a new position in shares of Arcus Biosciences during the first quarter valued at about $50,000. Finally, Strs Ohio purchased a new position in shares of Arcus Biosciences during the first quarter valued at about $67,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences News Summary

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Goldman Sachs raised its price target from $30 to $34 and kept a Buy rating, signaling stronger upside vs. the current share level and providing buy-side support for the stock. Goldman Sachs raises PT
• Positive Sentiment: HC Wainwright reiterated a Buy and a $32 target and nudged several near-term quarterly EPS forecasts slightly higher (Q2–Q4 2026) and materially lifted FY2030 to $0.44, suggesting improving longer‑term profitability expectations that can support multiple expansion. (Source: MarketBeat RCUS page) HC Wainwright notes
• Positive Sentiment: Arcus reported that its PEAK-1 trial is on track for full enrollment by year‑end 2026 and that cash runway extends into 2H 2028 — this reduces near‑term dilution risk and supports development continuity, a tangible de‑risking catalyst for biotech investors. PEAK-1 enrollment & cash runway
• Negative Sentiment: HC Wainwright cut FY2026, FY2027 and FY2028 EPS estimates (FY2026 now -$4.88) and lowered FY2029, reflecting a worse near‑term profitability profile than previously modeled; those downward revisions highlight the funding and milestone risks that still weigh on valuation. HC Wainwright notes
• Negative Sentiment: Recent quarterly results (reported May 5) showed an EPS miss and revenue decline year‑over‑year, underscoring execution and revenue challenges that remain an overhang until clinical readouts or commercial progress improve the top line. (See company earnings release and analyst commentary on MarketBeat.) Quarterly results

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.